India's clinical research landscape is evolving rapidly, with a groundbreaking proposal from the Indian Council of Medical Research (ICMR) set to transform how multicenter studies, including clinical trials, are ethically reviewed. The Draft Operational Guidelines for Single Ethics Review of Multicentre Research in India aim to replace the cumbersome process of multiple institutional ethics committee (EC) approvals with a streamlined single-review model. This initiative addresses longstanding bottlenecks that have hindered the efficiency and scalability of collaborative research across the country's diverse institutions.

Multicentre research—defined as studies conducted across multiple sites using a common protocol to answer shared questions—powers advancements in fields like oncology, infectious diseases, and public health. Yet, in India, the requirement for each participating site to secure separate EC approval has led to significant delays, inconsistent decisions, and resource strain. By designating one qualified EC from the participating sites to handle the comprehensive review, ICMR's proposal promises faster timelines while safeguarding participant rights and ethical standards.

🔬 The Current Landscape of Multicentre Clinical Trials in India

India has emerged as a global hub for clinical trials, boasting a market valued at approximately USD 1.68 billion in 2025 and projected to reach USD 3.62 billion by 2035, growing at a compound annual growth rate (CAGR) of nearly 8%. In 2024 alone, around 18,000 new trials were registered on the Clinical Trials Registry - India (CTRI), marking a 50% increase from the previous year. Multicentre trials, which involve coordination across hospitals, universities, and research institutes, are crucial for recruiting diverse patient populations and generating robust data.

However, the system mandates ethics review by each site's Institutional Ethics Committee (IEC), often registered with the Drugs Controller General of India (DCGI) or ICMR's Division of Health Research (DHR). This fragmented approach results in duplicated efforts: the same protocol undergoes repeated scrutiny, leading to median approval times of 59 days per EC (interquartile range 28-73 days) during even routine periods. For a trial spanning 10 sites, this could translate to months or years of delays, stifling investigator-initiated studies and investigator-sponsored trials (ISTs).

Stakeholders, including principal investigators (PIs) at medical colleges like AIIMS and IITs' biomedical departments, highlight how these hurdles deter collaborations between urban premier institutes and rural or underserved sites, limiting generalizability and equity in research.

Challenges Stemming from Multiple Ethics Reviews

The inefficiencies of parallel EC reviews are well-documented. Key issues include:

• Timeline Delays: Each EC conducts independent full-board reviews, with global benchmarks at 2-3 months per site versus streamlined international models using single Institutional Review Boards (IRBs).
• Inconsistency: Variations in risk categorization, informed consent templates, and procedural interpretations across ECs undermine protocol integrity.
• Resource Burden: Overloaded ECs, especially in teaching hospitals and universities, face backlogs, infrequent meetings (sometimes biannual), and shortages of trained members.
• Scalability Limits: Adding sites mid-study requires fresh approvals, complicating adaptive trials.
• Equity Gaps: Smaller institutions lack robust ECs, excluding them from national networks.

During the COVID-19 pandemic, these pain points intensified, with ethics submissions surging and approvals pressured for speed, exposing systemic gaps. Recent surveys of Indian clinical trial investigators reveal widespread agreement on regulatory reforms to curb such delays.

For academics pursuing research jobs or PhD/postdoc positions in clinical research, these barriers mean prolonged grant cycles and missed publication windows, impacting careers in India's burgeoning biotech sector.

ICMR's Vision: Introducing Single Ethics Review

The ICMR Bioethics Unit, under the National Centre for Disease Informatics and Research (NCDIR), unveiled the draft on February 10, 2026, inviting public comments until March 6, 2026. Aligned with the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017), it operationalizes single EC review for multicentre studies spanning clinical trials of drugs, biologics, vaccines, devices, epidemiology, and more.

Core principle: One designated EC—preferably from the coordinating site—performs a unified review, issuing a single approval letter covering all sites. Other site ECs provide inputs via an Initial Review Form but defer to the single EC, fostering trust and shared responsibility.

This builds on prior ICMR efforts like Joint Ethics Review (2024) but addresses their limitations in scalability and coordination.

Eligibility Criteria for the Single Ethics Committee

Not every EC qualifies. The guidelines specify rigorous standards:

Participating sites mutually select the single EC, ensuring buy-in. This setup is ideal for university-affiliated hospitals and networks like ICMR's Clinical Trials Network.

Photo by Sahaj Patel on Unsplash

Step-by-Step Process Under the Proposed Model

The guidelines outline a clear workflow:

1. Protocol Harmonization: Coordinating PI develops master protocol with site-specific appendices, secures scientific/funding approvals.
2. EC Selection: Consensus on single EC.
3. Submission: Comprehensive dossier including protocol, site details, consent forms, CVs, data plans (Table 1 in guidelines).
4. Review: Risk-based (expedited/full); assesses design, risks, consent, privacy (Table 2).
5. Approval: Unified letter with validity period, conditions.
6. Oversight: Risk-based monitoring, SAE reports (24h notification), annual continuing reviews.
7. Amendments/Closure: Expedited for new sites; final reports mandatory.

For clinical trials, CTRI registration and NDCT Rules, 2019 compliance are prerequisites.View full ICMR draft PDF

Roles and Responsibilities: A Collaborative Framework

Clear delineation prevents overlaps:

• Single EC: Full review, oversight, SAE adjudication.
• Coordinating PI: Submissions, communications, monitoring coordination.
• Site PIs/ECs: Local implementation, issue reporting, no veto power unless exceptional risks.
• Member Secretary: Administrative hub for reports.

This empowers research hubs like IIT Madras' biomedical engineering departments or AIIMS networks while including peripheral medical colleges.

Oversight Mechanisms to Ensure Participant Safety

Rigorous safeguards mitigate single-review risks:

• Site-specific Initial Review Forms flag local issues.
• Monitoring plans with audits/DSMBs for high-risk trials.
• SAE reporting timelines: 24 hours preliminary, 14 days detailed.
• Complaint resolution via single EC; deviations documented.
• Post-trial access and result dissemination mandated.

Alignment with Good Clinical Practice (GCP) ensures global comparability.

Anticipated Benefits and Impacts on Research Ecosystem

The model promises transformative gains:

• Faster Approvals: Slash timelines by 50-70%, enabling quicker patient access to innovations.
• Cost Savings: Reduced administrative burden, ideal for grant-funded university research.
• Inclusivity: Easier integration of tier-2/3 medical colleges and rural sites.
• Harmonization: Uniform standards boost data quality, international collaborations.
• Sector Boost: Supports India's goal to capture 10% global trials share by 2030.

Academics can explore clinical research jobs or postdoc opportunities in thriving networks.

Potential Concerns and Proposed Mitigations

Critics worry about diluted local oversight. Guidelines counter with:

• Exception clauses for site-specific high risks.
• Mutual trust protocols and training mandates.
• Digital repositories for transparency.

LinkedIn reactions praise it as "much-needed" but urge robust monitoring.

Photo by Big G Media on Unsplash

Expert Perspectives and Industry Reactions

Dr. Roli Mathur (ICMR Bioethics) emphasizes collaboration: "This accelerates timelines while protecting rights." Prithivi Raj NK calls it a "step forward for India." CRO leaders anticipate 20-30% efficiency gains. Universities like PGIMER Chandigarh eye lead EC roles.Submit comments to ICMR

For career advice, check how to craft a winning academic CV for research roles.

Future Outlook: Paving the Way for Research Excellence

If adopted post-consultation, expect pilot implementations in ICMR networks by late 2026, scaling to all DHR-funded studies. This aligns with New Drugs and Clinical Trials Rules, positioning India as an ethics-efficient innovator. Researchers, explore openings at university jobs, higher ed jobs, or rate professors via Rate My Professor. Share your views in comments below.